Sharekhan

Suven Life Sciences Ltd

Thu 11/09/2025,11:44:56 NSE: SUVEN

₹ 220.76 2.81 (1.29%)
BUY NOW Buy Suven Life Sciences Ltd Stock

Open Free Demat and Trading account in 15 minutes

Home Stock Suven Life Sciences Ltd

Thu 11/09/2025,11:57:0

Suven Life Sciences Ltd

Thu 11/09/2025,11:44:56 | NSE : SUVEN

₹ 220.762.81 (1.29%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 222.00

Previous Close

₹ 217.95

Volume

52490

Mkt Cap ( Rs. Cr)

₹5021.72

High

₹ 224.80

Low

₹ 219.35

52 Week High

₹ 299.99

52 Week Low

₹ 102.50

Book Value Per Share

₹ 8.51

Dividend Yield

0.00

Face Value

₹ 1.00

What’s Your Call?

Collective community sentiment on Suven Life Sciences Ltd

Your Vote -

Buy

63.67%

Hold

7.55%

Sell

28.78%

63.67%

278 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

67%

Sell Order Quantity

33%

Bid Price

Qty

220.21

4

220.00

20

220.00

20

220.00

5

220.00

42

Bid Total

39716

Bid Price

Qty

220.53

13

221.00

22

221.00

21

221.00

16

221.00

35

Bid Total

19649

Option Chain

Analyzes market sentiment, predicts Suven Life Sciences Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Suven Life Sciences - Shareholders meeting

    22 Aug 2025, 3:59PM Suven Life Sciences Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on August 22, 2025

  • Suven Life Sciences - Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    22 Aug 2025, 3:52PM Scrutinizer's report

  • Suven Life Sciences - Shareholders meeting

    22 Aug 2025, 3:47PM Suven Life Sciences Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on August 22, 2025

  • Suven Life Sciences - Shareholder Meeting / Postal Ballot-Outcome of AGM

    22 Aug 2025, 3:47PM 36th Annual General Meeting was held on 22nd August, 2025, summary of proceedings enclosed.

  • Suven Life Sciences - Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    22 Aug 2025, 3:52PM Scrutinizer's report

  • Suven Life Sciences - Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    22 Aug 2025, 3:52PM Scrutinizer's report

  • Suven Life Sciences - Copy of Newspaper Publication

    14 Aug 2025, 12:52PM Suven Life Sciences Limited has informed the Exchange about Copy of Newspaper Publication

  • Suven Life Sciences - Copy of Newspaper Publication

    14 Aug 2025, 12:49PM Suven Life Sciences Limited has informed the Exchange about Copy of Newspaper Publication

  • Suven Life Sciences - Press Release

    13 Aug 2025, 3:02PM Suven Life Sciences Limited has informed the Exchange regarding a press release dated August 13, 2025, titled ""News Release"".

  • Suven Life Sciences - Outcome of Board Meeting

    13 Aug 2025, 12:53PM Suven Life Sciences Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.

  • Suven Life Sciences - Outcome Of The Meeting Of Board Of Directors Of Suven Life Sciences Limited Held On August 13, 2025

    13 Aug 2025, 12:53PM Financial Results Q1 FY 2025-26

  • Suven Life Sciences - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    13 Aug 2025, 3:01PM Please find enclosed News Release of our company in relation to Q1 FY 2025-26 Financial Results.

  • Suven Life Sciences posts Q1 net loss of Rs 14.78 cr

    13 Aug 2025, 1:20PM The company reported standalone net loss during the quarter stood at Rs 14.78 crore as compared to net loss of Rs 7.67 crore in the previous year quar

  • Suven Life Sciences - Board Meeting Intimation for Consider & Approve Un-Audited Financial Results (Standalone And Consolidat

    5 Aug 2025, 4:04PM Suven Life Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2025 ,inter alia, to consider

  • Suven Life Sciences - Updates

    30 Jul 2025, 2:04PM Suven Life Sciences Limited has informed the Exchange regarding 'Business Responsibility and Sustainability Report for FY 2024-25'.

  • Suven Life Sciences - Business Responsibility and Sustainability Reporting (BRSR)

    30 Jul 2025, 2:02PM Please find enclosed BRSR FY 2024-25

  • Suven Life Sciences - Notice Of 36Th Annual General Meeting (AGM) Of The Company

    30 Jul 2025, 2:00PM Notice of 36th Annual General Meeting

  • Suven Life Sciences - Shareholders meeting

    30 Jul 2025, 1:59PM Suven Life Sciences Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on August 22, 2025

  • Suven Life Sciences - Reg. 34 (1) Annual Report.

    30 Jul 2025, 1:43PM Annual Report 2024-25 and Notice of 36th Annual General Meeting (AGM) of the Company

  • Suven Life Sciences - ESOP/ESOS/ESPS

    24 Jul 2025, 3:58PM Suven Life Sciences Limited has informed the Exchange regarding Allotment of 214000 Shares.

  • Suven Life Sciences - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

    24 Jul 2025, 3:57PM Allotment of 2,14,000 Equity Shares upon exercise of vested options under SLSL ESOP 2020

  • Suven Life Sciences has submitted to BSE the Shareholding Pattern for the Period Ended July 16, 2025

    23 Jul 2025, 12:11PM As of July 2025, 67.42% is owned by Indian Promoters and 32.57% by Public. <p align=justify> Top two Promoters holding highest number of shares of Suv

  • Suven Life Sciences has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2025

    21 Jul 2025, 12:31PM As of June 2025, 70.26% is owned by Indian Promoters and 29.73% by Public. <p align=justify> Top two Promoters holding highest number of shares of Suv

  • Suven Life Sciences - Alteration Of Capital and Fund Raising-XBRL

    16 Jul 2025, 3:59PM SUVEN LIFE SCIENCES LIMITED has informed the Exchange regarding Allotment of Securities

  • Suven Life Sciences - Outcome of Board Meeting

    16 Jul 2025, 2:55PM Suven Life Sciences Limited has informed the Exchange regarding Board meeting held on July 16, 2025. Allotment of 91,86,490 Equity Shares of the Comp

  • Suven Life Sciences - Board Meeting Outcome for Outcome Of The Meeting Of Board Of Directors Of Suven Life Sciences Limited H

    16 Jul 2025, 2:55PM Allotment of 91,86,490 Equity Shares of the Company on preferential basis upon conversion 91,86,490 fully paid warrants

  • Suven Life Sciences - Press Release

    16 Jul 2025, 12:51PM Suven Life Sciences Limited has informed the Exchange regarding a press release dated July 16, 2025, titled ""Suven Life Sciences announces First Pati

  • Suven Life Sciences - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    16 Jul 2025, 1:01PM Please find enclosed News Release of our company

  • Suven Life Sciences - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    9 Jul 2025, 10:59AM Certificates for quarter ended 30th June, 2025

  • Suven Life Sciences - Certificate under SEBI (Depositories and Participants) Regulations, 2018

    9 Jul 2025, 10:59AM Suven Life Sciences Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018

  • Suven Life Sciences - Alteration Of Capital and Fund Raising-XBRL

    3 Jul 2025, 5:13PM SUVEN LIFE SCIENCES LIMITED has informed the Exchange regarding Allotment of Securities

  • Suven Life Sciences - Outcome of Board Meeting

    3 Jul 2025, 4:58PM Suven Life Sciences Limited has informed the Exchange regarding Board meeting held on July 03, 2025 - Allotment of 6,40,02,999 warrants convertible i

  • Suven Life Sciences - Board Meeting Outcome for Allotment Of 6,40,02,999 Warrants Convertible Into Equity Shares

    3 Jul 2025, 4:58PM The Board of Directors of the Company in its meeting held today i.e. 03rd July, 2025 has allotted convertible Warrants to 23 allottees.

  • Suven Life Sciences - Trading Window

    27 Jun 2025, 1:01PM Suven Life Sciences Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulatio

  • Suven Life Sciences - Trading Window-XBRL

    27 Jun 2025, 12:54PM SUVEN LIFE SCIENCES LIMITED has informed the Exchange about Closure of Trading Window

  • Suven Life Sciences

    1 Mar 2024 , 10:42AM Suven Announces Merger of Cohance Lifesciences, Forging Integrated Pharma CDMO Leadership in India. Transformative Merger with 2x Scale and Double-Digit EPS Accretion in the first year. Suven poised to become a leading integrated CDMO player in India and globally; will have multiple engines of growth that will help drive stability in financial performance and growth. Cohance's ADC Platform addition further strengthens Suven’s position in the high growth CDMO segment also adds lifecycle management capabilities for Innovators. Positive

  • Suven Life board nod raising upto Rs. 400 cr via rights issue

    13 Oct 2022 , 10:58AM Suven Life: To issue 1 right share for every 2 held

  • Suven Life board approves Rs. 400 cr fund raising

    24 Jun 2022 , 12:57PM Suven Life board approves raising up to Rs. 400 cr via allotment of equity shares on rights basis

  • Suven Life Sciences board to consider fundraising on June 24

    21 Jun 2022 , 10:16AM Board to consider Right Issue of equity shares

  • Suven Life Sciences

    17 Aug 2021 , 9:34AM Suven Life Sciences: To commence phase 3 global clinical trials for its NCE (New Chemical Entitiy) SUVN – 502 (Masupiridine) which is indicated for treatment of Agitation and aggression in Alzheimer’s type dementias. The patient enrollment would be commencing from mid September 2021 and is likely to be completed in about 36 months with and the topline result expected by the end of year 2024. The commencement of phase 3 trials is positive.

  • Suven Life Sciences

    13 Jan 2021 , 10:31AM As per media news PE investors - Blackstone, Warburg Pincus and CVC Capital Partners have been shortlisted to buy a controlling stake in Hyderabad-based Suven Pharmaceuticals – which is a leading contract manufacturer. The promoters currently hold 60% stake in the company and are looking to halve their stake. The share sale would trigger an open offer for another 26% stake, which would result in the new investor getting a control of around 56% ownership. Positive

  • Suven Life Sciences announces top-line results of SUVN-502

    2 Dec 2019 , 10:33AM Suven Life Sciences announces Top-Line Results of SUVN-502 (Masupirdine) Phase 2A Study in Patients with Moderate Alzheimer''s Disease (AD)

  • Suven Life Sciences gets 4 product patents

    4 Apr 2019 , 10:17AM Suven Life Sciences secures Product Patents in Israel, Japan, New Zealand and Sri Lanka

  • Suven Life Sciences secures new product patents

    29 Mar 2019 , 10:36AM Suven Life Sciences secures Product Patents in Eurasia, Europe, South Korea and Sri Lanka

  • Suven to buy assets of Aceto Corporation

    8 Mar 2019 , 11:13AM Suven enters into "Stalking Horse”" agreement to buy rising pharmaceuticals

  • Suven Q3FY2019 operating performance below expectation

    6 Feb 2019 , 10:47AM Suven Q3FY2019 net profit falls by 27.1% to Rs. 25.2 crore

  • Suven Life gains on securing product patents

    16 Jan 2019 , 12:11PM Suven Life Sciences rises over 3% to Rs. 226.2, after the company said it secured product patents in Australia and Singapore

  • Suven Life Science secures product patents in Brazil & Eurasia

    27 Dec 2018 , 11:13AM Suven Life bags product patent from Brazil and from Eurasia corresponding to the New Chemical Entities

  • Suven Lifescience reports disappointing performance for Q2FY2019

    15 Nov 2018 , 10:40AM Suven Lifescience Q2 net profit falls by 32.2% to Rs. 31 crore for the quarter ended September 30, 2018

  • Suven Life gets patents in Australia, Hong Kong

    13 Nov 2018 , 11:29AM Suven Life Sciences secures product patents in Australia and Hong Kong

  • Suven secures Product Patents in Israel and Japan

    6 Nov 2018 , 11:46AM Suven Life Sciences bags product patents from Israel and Japan

  • Suven gets product patents from Canada, Sri Lanka

    25 Sep 2018 , 12:06PM Suven Life Sciences secures Product Patents in Canada and Sri Lanka

  • Suven Life secures Product Patents in China & Eurasia

    29 Aug 2018 , 11:41AM Suven Life announces the grant of one (1) product patent from China (CN105873920) and one (1) product patent from Eurasia (029951)

  • Suven Life Q1 profit number misses estimates

    16 Aug 2018 , 11:41AM Suven Life Sciences: profit number misses estimates marginally due to high tax; mixed bag numbers

  • uven Life secures product patents

    17 May 2018 , 12:53PM Suven Life bags two product patents from Australia and one product patent from Singapore

  • Suven Life secures product patents from Norway

    22 Mar 2018 , 12:59PM Suven Life secures product patents from Norway, South Korea and Singapore regulators corresponding to the NCEs for the treatment of disorders allied with Neurodegenerative diseases

  • Suven Life up after securing product patents

    16 Nov 2017 , 12:45PM Suven Life rises over 5% at Rs200.7, after securing product patents in Hong Kong, India and USA

  • Suven up on securing product patent from New Zealand

    10 Oct 2017 , 1:28PM Suven Life rises by 10% to Rs198.8, after securing a product patent in New Zealand corresponding to the NCEs

  • Process patents from across the world for Suven Life Science

    17 Aug 2017 , 11:41AM Suven Life Science gets process patents from Europe, Japan and New Zealand
Load More
Show Less

Key fundamentals

Evaluate the intrinsic value of Suven Life Sciences Ltd stock 

Name March-25 March-24 March-23 March-22 March-21
Assets 799.511 845.3762 853.4445 476.4615 402.047
Liabilities 799.511 845.3762 853.4445 476.4615 402.047
Equity 21.8074 21.8074 21.8074 14.5382 12.7282
Gross Profit -51.9374 -30.9367 -27.7439 -36.6424 -30.547
Net Profit -47.0798 -8.0083 -20.1272 -36.2486 -22.6321
Cash From Operating Activities -47.3907 -20.563 -10.0872 -36.6229 -36.6849
NPM(%) -707.34 -68.48 -148.65 -306.04 -167.91
Revenue 6.6558 11.6929 13.5392 11.8443 13.4783
Expenses 58.5932 42.6296 41.2831 48.4867 44.0253
ROE(%) -24.31 -4.13 -10.39 -18.72 -11.68

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day
14 Feb 2019 1.5 150 0 193.05
06 Feb 2018 1.5 150 0 198.35
08 Feb 2017 1 100 0 172.3
14 Mar 2016 1 100 0 199.45
14 Mar 2016 1 100 0 201.9
23 Jul 2015 0.6 60 0 286.2
24 Jul 2014 2 200 0 90.5
24 Jul 2014 0.5 50 0 93.9
01 Aug 2013 0.3 30 0 28.1
17 Sep 2012 0.3 30 0 18.25
01 Aug 2011 0.25 25 0 21.75
19 Jul 2010 0.25 25 0 33.5
14 Sep 2009 0.25 25 0 22.5
11 Sep 2008 0.25 25 0 25.8
21 Sep 2007 0.25 25 0 41.35
25 Sep 2006 1 50 0 73.5

Peers

Other companies within the same industry or sector that are comparable to Suven Life Sciences Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 810.00 0.77 73.44 124.50 301.39 0.62
Lotus Eye Hospital and Institute Ltd 121.90 0.42 393.23 453.67 3.55 0.00
Vaishali Pharma Ltd 12.09 0.33 403.00 233.84 3.13 0.00
Astec Lifesciences Ltd 862.40 1.17 0.00 427.82 -604.77 0.00

Company Info

Brief History and business of the Company Suven Pharmaceuticals Limited was promoted in 1989 by Mr.Jasti Venkateswarlu and Mrs. Jasti Sudha Rani for the manufacture of bulk drugs and drug intermediates. The Company was incorporated as a Private Limited Company on 9th March, 1989 in the state of Andhra Pradesh.Subsequently on 4th January, 1995 it was converted into a Public Limited Company in terms of special resolution dated 25.11.94 U/s. 31(1)/44 of Companies Act. - The Company deveops and manufactures drug intermediates, under contract from the drug's global patent holders. 2000 - The Company has entered into agreement with NSDL and CDSL for dematerialisation of shares. - Company bags export orders of Rs 21 cr 2001 - Borregaard Industries Ltd, Norway, acquires 15% stake in the company 2002- An accident occurred at the company's Suryapet Unit AS when a transporters vehicle entered the factory premises on November 17, 2002 -Pfizer Ltd and Suven Pharmaceuticals Ltd have tied up with the Bombay College of Pharmacy to set up an academy for clinical excellence (ACE) , in Mumbai. 2003-Borregaard Industries Ltd, a Norwegean pharma player has offloaded its entire 17.05 per cent stake ( 7.50 lakh equity shares) in Suven Life Sciences Ltd -Suven Life Sciences USA LLC a wholly owned subsidiary of Suven Pharmaceuticals Ltd has acquired Synthon Chiragenics Corporation New Jersey USA 2004 -Suven Life Sciences Ltd has informed the stock exchanges that its shareholders at the extraordinary general meeting held on Jan 05 have approved the sub-division of equity shares into face value of Rs 2 each from the face value of Rs 10 each. -Suven Life Sciences BoD approves preferential shares issue -Suven Life Sciences Ltd has said that its board of directors on Jan 19 has allotted 30 lakh equity shares of face value of Rs 2 each on preferential basis to four investors. While Emerging Markets Management LLC was allotted 10 lakh shares, Aeneas Portfolio Company LP 8.75 lakh shares, Commonwealth Equity Fund Ltd, a sub-account of Batterymarch Financial Management Inc, 6.25 lakh shares and Mr Rambabu Chirumamilla was given 5 lakh shares. -Two units of Suven Life (Suryapet & Jeedimetla) get ISO confirmation 2007 - Suven Life Sciences Ltd (Suven) on November 27, 2007 has announced that the European Patent Office (EPO) granted Two Patents, 1523486 and 1581538 to Suven and are valid until June 2022. -The Company has issued Bonus Shares in the Ratio of 1:1. - The Company has splits its face value from Rs2/- to Rs1/-. 2009 - Suven Life Sciences has secured two U.S. patents relating to new chemical entities (NCEs) for treatment of disorders associated with neurodegenerative diseases - Suven Life Sciences Ltd (Suven) announces today that the European Patent Office (EPO) has Issued 3 new Patents: EP1537113, EP1704154 and EP1856132 corresponding to three New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid until 2022,23 and 24 respectively. 2010 -Suven Secures Two product patents in China and Russia -Suven Life Sciences secures 5th Product Patent from US patent office for their NCE to treat Central Nervous System -Suven Life Sciences bagged the eight product patent from European Patent Office (EPO) for their NCE to treat Central Nervous System (CNS) disorders. -Suven Life Secures Three Australian Patents on NCEs -Suven gets two patents from Japanese Patent Office for NCE's 2011 -Suven's Unit-III receives US FDA Acceptance -Suven Life Sciences secures 7 Product Patents for their NCEs in several key markets in the world -Suven Life Sciences bags "Bio-Excellence Award at Bangalore India Bio 2011 -Suven Life Sciences secures 2 Product Patents for their NCEs in the key markets in the world -Suven Life Sciences bags Pharmexcil's Gold "Patent Award" 2012 -Suven Life Sciences secures 3 Product Patents for their NCEs in Mexico and USA -Suven Life Sciences gets 4 Product Patents in Japan, Australia, Europe and Eurasia -Suven Life Sciences bags Pharmexcil's "Platinum Patent Award" -Suven Life Sciences secures 5 Product Patents for their NCEs in China & Korea. 2013 - Suven Life Sciences bags 4 Product Patents for their NCEs in China, Mexico and New Zealand" - Suven Life secures three Product Patents for their NCEs in Canada and Eurasia" - Suven Life secures two (2) Product Patents for their NCEs in Europe - The Company has recommended Dividend Re. 30 paisa per equity share of face value of Re. 1/-. 2014 - SUVEN'S PASHAMYLARAM'S UNIT RECEIVES US FDA ACCEPTANCE - Suven Life Sciences bags Pharmexcil's 'Gold Patent Award' for NCE's and 'Outstanding Export Performance Award' for Contract Research and Manufacturing. - Suven Life Sciences awarded Forbes Asia's "Best Under A Billion" Award 2015 - Suven initiated Multiple Ascending Dose (MAD) studies in Phase 1 clinical Trial for their investigational compound SUVN-G3031 - Suven Life Sciences bags Pharmexcil's Gold Patent Award 2016 -Suven Life Sciences gets product patent for NCEs. -Suven Life Sciences secures two (2) Product Patents in Europe and Israel. 2017 -"Suven Life Sciences secures Product Patents in Canada and India". -"Suven Life Sciences secures Product Patents in Eurasia and Norway". -Suven bags product patent for treatment of neuro diseases. 2018 -"Suven Life Sciences secures Product Patents in Brazil andEurasia". -"Suven Life Sciences secures Product Patents in Australia andHong Kong". 2019 -"Suven completes the purchase of assets of Rising Pharmaceuticals through its joint venture partner, Shore Suven Pharma Inc.". -"Suven Life Sciences secures Product Patents in Australia and Singapore". 2022 -Company issued rights shares of Rs. 1 in the ratio of 1:2 at a premium of Rs. 54 per share. 2023 -Suven completed enrollment of patients to the phase-2(PoC) clinical study of SUVN-G3031 in US,CANADA.

Brief History and business of the Company Suven Pharmaceuticals Limited was promoted in 1989 by Mr.Jasti Venkateswarlu and Mrs. Jasti Sudha Rani for the manufacture of bulk drugs and drug intermediates. The Company was incorporated as a Private Limited Company on 9th March, 1989 in the state of Andhra Pradesh.Subsequently on 4th January, 1995 it was converted into a Public Limited Company in terms of special resolution dated 25.11.94 U/s. 31(1)/44 of Companies Act. - The Company deveops and manufactures drug intermediates, under contract from the drug's global patent holders. 2000 - The Company has entered into agreement with NSDL and CDSL for dematerialisation of shares. - Company bags export orders of Rs 21 cr 2001 - Borregaard Industries Ltd, Norway, acquires 15% stake in the company 2002- An accident occurred at the company's Suryapet Unit AS when a transporters vehicle entered the factory premises on November 17, 2002 -Pfizer Ltd and Suven Pharmaceuticals Ltd have tied up with the Bombay College of Pharmacy to set up an academy for clinical excellence (ACE) , in Mumbai. 2003-Borregaard Industries Ltd, a Norwegean pharma player has offloaded its entire 17.05 per cent stake ( 7.50 lakh equity shares) in Suven Life Sciences Ltd -Suven Life Sciences USA LLC a wholly owned subsidiary of Suven Pharmaceuticals Ltd has acquired Synthon Chiragenics Corporation New Jersey USA 2004 -Suven Life Sciences Ltd has informed the stock exchanges that its shareholders at the extraordinary general meeting held on Jan 05 have approved the sub-division of equity shares into face value of Rs 2 each from the face value of Rs 10 each. -Suven Life Sciences BoD approves preferential shares issue -Suven Life Sciences Ltd has said that its board of directors on Jan 19 has allotted 30 lakh equity shares of face value of Rs 2 each on preferential basis to four investors. While Emerging Markets Management LLC was allotted 10 lakh shares, Aeneas Portfolio Company LP 8.75 lakh shares, Commonwealth Equity Fund Ltd, a sub-account of Batterymarch Financial Management Inc, 6.25 lakh shares and Mr Rambabu Chirumamilla was given 5 lakh shares. -Two units of Suven Life (Suryapet & Jeedimetla) get ISO confirmation 2007 - Suven Life Sciences Ltd (Suven) on November 27, 2007 has announced that the European Patent Office (EPO) granted Two Patents, 1523486 and 1581538 to Suven and are valid until June 2022. -The Company has issued Bonus Shares in the Ratio of 1:1. - The Company has splits its face value from Rs2/- to Rs1/-. 2009 - Suven Life Sciences has secured two U.S. patents relating to new chemical entities (NCEs) for treatment of disorders associated with neurodegenerative diseases - Suven Life Sciences Ltd (Suven) announces today that the European Patent Office (EPO) has Issued 3 new Patents: EP1537113, EP1704154 and EP1856132 corresponding to three New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid until 2022,23 and 24 respectively. 2010 -Suven Secures Two product patents in China and Russia -Suven Life Sciences secures 5th Product Patent from US patent office for their NCE to treat Central Nervous System -Suven Life Sciences bagged the eight product patent from European Patent Office (EPO) for their NCE to treat Central Nervous System (CNS) disorders. -Suven Life Secures Three Australian Patents on NCEs -Suven gets two patents from Japanese Patent Office for NCE's 2011 -Suven's Unit-III receives US FDA Acceptance -Suven Life Sciences secures 7 Product Patents for their NCEs in several key markets in the world -Suven Life Sciences bags "Bio-Excellence Award at Bangalore India Bio 2011 -Suven Life Sciences secures 2 Product Patents for their NCEs in the key markets in the world -Suven Life Sciences bags Pharmexcil's Gold "Patent Award" 2012 -Suven Life Sciences secures 3 Product Patents for their NCEs in Mexico and USA -Suven Life Sciences gets 4 Product Patents in Japan, Australia, Europe and Eurasia -Suven Life Sciences bags Pharmexcil's "Platinum Patent Award" -Suven Life Sciences secures 5 Product Patents for their NCEs in China & Korea. 2013 - Suven Life Sciences bags 4 Product Patents for their NCEs in China, Mexico and New Zealand" - Suven Life secures three Product Patents for their NCEs in Canada and Eurasia" - Suven Life secures two (2) Product Patents for their NCEs in Europe - The Company has recommended Dividend Re. 30 paisa per equity share of face value of Re. 1/-. 2014 - SUVEN'S PASHAMYLARAM'S UNIT RECEIVES US FDA ACCEPTANCE - Suven Life Sciences bags Pharmexcil's 'Gold Patent Award' for NCE's and 'Outstanding Export Performance Award' for Contract Research and Manufacturing. - Suven Life Sciences awarded Forbes Asia's "Best Under A Billion" Award 2015 - Suven initiated Multiple Ascending Dose (MAD) studies in Phase 1 clinical Trial for their investigational compound SUVN-G3031 - Suven Life Sciences bags Pharmexcil's Gold Patent Award 2016 -Suven Life Sciences gets product patent for NCEs. -Suven Life Sciences secures two (2) Product Patents in Europe and Israel. 2017 -"Suven Life Sciences secures Product Patents in Canada and India". -"Suven Life Sciences secures Product Patents in Eurasia and Norway". -Suven bags product patent for treatment of neuro diseases. 2018 -"Suven Life Sciences secures Product Patents in Brazil andEurasia". -"Suven Life Sciences secures Product Patents in Australia andHong Kong". 2019 -"Suven completes the purchase of assets of Rising Pharmaceuticals through its joint venture partner, Shore Suven Pharma Inc.". -"Suven Life Sciences secures Product Patents in Australia and Singapore". 2022 -Company issued rights shares of Rs. 1 in the ratio of 1:2 at a premium of Rs. 54 per share. 2023 -Suven completed enrollment of patients to the phase-2(PoC) clinical study of SUVN-G3031 in US,CANADA.

Read More

Parent Organisation

Suven Life Sciences Ltd.

Founded

09/03/1989

Managing Director

Mr.Venkateswarlu Jasti

NSE Symbol

SUVENEQ

FAQ

The current price of Suven Life Sciences Ltd is ₹ 220.76.

The 52-week high for Suven Life Sciences Ltd is ₹ 224.80 and the 52-week low is ₹ 219.35.

The market capitalization of Suven Life Sciences Ltd is currently ₹ 5021.72. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.

To buy Suven Life Sciences Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.

To invest in Suven Life Sciences Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Suven Life Sciences Ltd shares.

The CEO of Suven Life Sciences Ltd is Mr.Venkateswarlu Jasti, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.

OPEN FREE* DEMAT ACCOUNT